Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/SLCTR/2018/009
SLCTR/2018/009TerminatedPhase 3

A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi- centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add-On to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and Hypertension

Dr Shohini Ghosh0 sitesStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 3
Status
Terminated
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •1.Male and female subjects in the age range 30-70 years (both inclusive)
  • •2.BMI in the range 23-39 (inclusive) kg/m2
  • •3. HbA1c > 7.5 %
  • •4. Stable therapy of < 2 oral hypoglycemic agents for at least two months prior to screening at doses that are appropriate for the duration of the study in the judgment of the investigator.
  • •5. Non HDL cholesterol > 160 mg/dL
  • •6. Mean Arterial Pressure (MAP) >100 mm Hg based on average of 24 hours’ ambulatory blood pressure monitoring with or without anti-hypertensive treatment (subjects will have to be on stable dose of anti hypertensive treatment for at least two months prior to screening); Dose should be appropriate for the duration of the study in the judgment of the investigator.
  • •7. Willing to give written informed consent
  • •8. Ability to adhere to the study restrictions and assessments schedule

Exclusion Criteria

  • •1.Uncontrolled hypertension: SBP of >180 mmHg and DBP >110 mmHg based on 24 hours Ambulatory Blood Pressure Monitoring
  • •2.HbA1C > 10% at screening
  • •3.Serum triglycerides >400 mg/dL
  • •4.LDL-cholesterol >300 mg/dL or medical history/clinical evidence of familial hyperlipidemic disorder.
  • •5.Subjects on insulin or SGLT2 inhibitors
  • •6.ACS or stroke or any revascularization within last 6 months.
  • •7.Subjects having untreated thyroid dysfunction (TSH <0.3 or >5.5 µIU/mL) or hormone related obesity disorder
  • •8.Subjects with liver enzymes (SGOT, SGPT) more than 3X of upper limit of normal value
  • •9.eGFR <30 mL/min as evaluated by MDRD method
  • •10.Seropositive for HIV, Hepatitis B or Hepatitis C
  • •11.History of alcohol or drug abuse, psychiatric disorder, any bleeding disorder, malignancy in last 3 years
  • •12.Pregnant or lactating women
  • •13. Female of childbearing potential, who are neither surgically sterilized nor willing to use reliable contraceptive methods (double barrier methods or intrauterine device).
  • •14.Male subjects with partners of childbearing potential not willing to use reliable contraception methods.
  • •15.Clinically significant abnormal physical findings, laboratory results, ECG findings and/or any other clinical observation or history during the screening examination, which would interfere with the objectives of the study.
  • •16.Intake of any investigational drug within 3 months prior to the first dose of study drug.
  • •17.In the opinion of the investigator, subject is unable to cooperate with any study procedures, unlikely to adhere to the study procedures, keep appointments, or plan to relocate during the study.

Investigators

Sponsor
Dr Shohini Ghosh

Similar Trials

Completed
Phase 3
To evaluate the efficacy and safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects with Diabetes, Dyslipidemia and Hypertensio
CTRI/2017/11/010555Torrent Pharmaceutical Ltd986
Completed
Phase 3
A Phase III, Clinical Trial to Evaluate the safety, tolerability and efficacy of 2 Fixed dose combinations of Azelnidipine and Chlorthalidone when compared with fixed dose combination of Amlodipine and Hydrochlorothiazide in patients with Stage II hypertension.
CTRI/2020/03/023708Synokem Pharmaceuticals Ltd210
Active, not recruiting
Phase 1
A study to assess effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) in patients having acute respiratory distress syndrome (ARDS)
EUCTR2014-005260-15-CZFaron Pharmaceuticals Ltd300
Active, not recruiting
Phase 1
A study to assess effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) in patients having acute respiratory distress syndrome (ARDS)Adult patients diagnosed with moderate or severe Acute Respiratory Distress Syndrome (ARDS)MedDRA version: 20.0 Level: LLT Classification code 10003083 Term: ARDS System Organ Class: 100000004855
EUCTR2014-005260-15-DEFaron Pharmaceuticals Ltd296
Active, not recruiting
Phase 1
A study to assess effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) in patients having acute respiratory distress syndrome (ARDS)
EUCTR2014-005260-15-ESFaron Pharmaceuticals Ltd300